Luis F Santamaria-Babi

Prof. Dr. Luis F Santamaria-Babi

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
EREster Ruiz-Romeu
Ester Ruiz-Romeu
MFMarta Ferran
Marta Ferran
MSMarc Sagristà
Marc Sagristà
JGJulià Gómez
Julià Gómez
AGAna Giménez-Arnau
Ana Giménez-Arnau
LSLuis F Santamaria-Babi
Luis F Santamaria-Babi

1 April 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MFMarta Ferran
Marta Ferran
AGAna B. Galván
Ana B. Galván
CRCatalina Rincón
Catalina Rincón
EREster R. Romeu
Ester R. Romeu
MSMarc Sacrista
Marc Sacrista
LSLuis F Santamaria-Babi
Luis F Santamaria-Babi

1 August 2016 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
EREster Ruiz-Romeu
Ester Ruiz-Romeu
MFMarta Ferran
Marta Ferran
AGAna Giménez-Arnau
Ana Giménez-Arnau
BBBeata Bugara
Beata Bugara
BLBarbara Lipert
Barbara Lipert
LSLuis F Santamaria-Babi
Luis F Santamaria-Babi

1 July 2022 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
Esther Serra-BaldrichEsther Serra-Baldrich
Esther Serra-Baldrich
LSLuis F Santamaria-Babi
Luis F Santamaria-Babi
JSJ. Francisco Silvestre
J. Francisco Silvestre
Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling. As the immune and nervous systems are interrelated, IL-31 has a key role in the treatment of atopic dermatitis and prurigo nodularis. Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling. It reduces inflammation and lesion severity in atopic dermatitis and prurigo nodularis by restoring epithelial function and promoting skin barrier integrity. This review synthesizes the latest information on the functions of IL-31 and presents the current evidence, including clinical trial results, on the use of nemolizumab in the treatment of atopic dermatitis and prurigo nodularis.

19 April 2013 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
MFMarta Ferran
Marta Ferran
EREster R. Romeu
Ester R. Romeu
CRCatalina Rincón
Catalina Rincón
MSMarc Sagristà
Marc Sagristà
AAAna M. Giménez Arnau
Ana M. Giménez Arnau
LSLuis F Santamaria-Babi
Luis F Santamaria-Babi
T lymphocytes expressing the CLA antigen constitute a subset of effector memory lymphocytes that are functionally involved in T‐cell‐mediated cutaneous diseases. Skin‐seeking lymphocytes recirculate between inflamed skin and blood during cutaneous inflammation. Many studies in different T‐cell‐mediated inflammatory cutaneous diseases have clearly related their pathologic mechanisms to CLA+ T cells. Based on common features of these cells in different cutaneous disorders mediated by T cells, we propose that circulating CLA+T cells could constitute very useful peripheral cellular biomarkers for T‐cell‐mediated skin diseases.

23 March 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
CJCarmen de Jesús-Gil
Carmen de Jesús-Gil
LSLídia Sans-De SanNicolàs
Lídia Sans-De SanNicolàs
IGIrene García-Jiménez
Irene García-Jiménez
MFMarta Ferran
Marta Ferran
ACAntonio Celada
Antonio Celada
LSLuis F Santamaria-Babi
Luis F Santamaria-Babi
Circulating memory T cells are heterogeneous in their tissue tropism. The skin-seeking T cell subset expresses the cutaneous lymphocyte-associated antigen (CLA) on their surface. CLA+ memory T cells not only migrate from blood to skin but also recirculate between blood and skin. Studying CLA+ memory T cells in cutaneous diseases has allowed a better understanding of immune-inflammatory mechanisms that take place. The analysis of the phenotypical features of these cells, their antigen specificity, cytokine production profile, and changes in relationship to clinical status and therapies among other characteristics have led to the concept that they constitute peripheral cellular biomarkers in T cell-mediated cutaneous conditions. CLA+ memory T cells are of relevance in the pathogenesis of several cutaneous diseases, such as psoriasis (PSO), atopic dermatitis, vitiligo, and drug-induced allergic reactions, to name a few. The interaction of circulating CLA+ T cells with skin-resident cells has been investigated in different ex vivo coculture models made out of clinical samples. Interestingly, microbes that are present in the skin or related with human skin diseases are preferentially recognized by CLA+ T cells. Thus, the interaction of Streptococcus pyogenes with CLA+ T cells in PSO is providing novel concepts that help to understand disease immunopathogenesis. The goal of this review is to present latest results in the field of CLA+ T cells in T cell-mediated inflammatory skin diseases and their translational relevance for human immunodermatology.